Comparison of the effects of olpasiran and placebo on risk of coronary heart disease death, myocardial infarction (MI) or urgent coronary revascularisation
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
